ARS Pharmaceuticals, Inc.

As of June 30, 2026, ARS Pharmaceuticals, Inc. carries a market capitalization of 796.50M, placing it among publicly traded companies globally. Its enterprise value stands at 749.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ARS Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 25, 2027.

As of June 30, 2026, ARS Pharmaceuticals, Inc. has 99.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.79, and the price-to-book ratio stands at 63.66.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 749.33M versus a market cap of 796.50M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ARS Pharmaceuticals, Inc. maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 772.67, indicating elevated leverage, while an interest coverage ratio of -43.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ARS Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -210.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -76.53, reflecting losses generated across the asset base. The company generates approximately 720,659.48 in revenue per employee across its workforce of 162.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.28 indicates how many times ARS Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on November 6, 2026, ARS Pharmaceuticals, Inc.'s stock has declined approximately 65.95% over the past 52 weeks. The 50-day moving average sits at 4.29, while the 200-day moving average is 7.20.

Over the twelve months ended June 30, 2026, ARS Pharmaceuticals, Inc. generated 116.93M in revenue and converted that into -215.43M in net income, yielding earnings per share of -2.17. EBITDA reached -216.27M, while operating income came in at -216.27M.

As of June 30, 2026, ARS Pharmaceuticals, Inc. holds 143.85M in cash and equivalents against 96.68M in total debt, resulting in a net debt position of 88.51M. Total book value stands at 12.51M, with working capital of 150.65M providing operational flexibility.

ARS Pharmaceuticals, Inc. produced -196.40M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -197,000.00 in capital expenditures, free cash flow totaled -196.60M - equivalent to -1.98 per share.

Over the twelve months ended June 30, 2026, ARS Pharmaceuticals, Inc. posted a gross margin of 71.37, reflecting its pricing power and cost economics. The operating margin of -184.96 and net profit margin of -184.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -24.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.12, meaning ARS Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ARS Pharmaceuticals, Inc. has an Altman Z-Score of -2.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.